ArticleFrontiers in immunology2025

Synergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for relapsed/refractory peripheral T cell lymphoma.

Ling Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.